
Months after big financing round, Touchlight signs supply agreement for Versameb's pipeline
A UK-based CDMO has landed a supply agreement with Versameb to provide its doggybone DNA for the company’s pipeline, including for its lead candidate to treat stress urinary incontinence.
Touchlight will supply Versameb with its enzymatic DNA as the biotech prepares to enter VMB-100 into Phase I clinical trials in the second half of this year. The deal will allow Versameb to utilize Touchlight’s dbDNA, also called doggybone DNA, for all future pipeline products.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.